Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 940 Cr.
- Current Price ₹ 798
- High / Low ₹ 1,416 / 775
- Stock P/E 32.5
- Book Value ₹ 217
- Dividend Yield 0.12 %
- ROCE 19.6 %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 131 to 63.6 days.
- Company's working capital requirements have reduced from 76.0 days to 54.0 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
213 | 620 | |
184 | 575 | |
Operating Profit | 29 | 46 |
OPM % | 14% | 7% |
3 | 5 | |
Interest | 0 | 1 |
Depreciation | 1 | 2 |
Profit before tax | 30 | 47 |
Tax % | 20% | 19% |
24 | 38 | |
EPS in Rs | 17.69 | 24.64 |
Dividend Payout % | 4% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 191% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 41% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -32% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Equity Capital | 1 | 6 |
Reserves | 156 | 250 |
14 | 23 | |
161 | 154 | |
Total Liabilities | 333 | 433 |
14 | 16 | |
CWIP | 0 | 0 |
Investments | 105 | 186 |
215 | 231 | |
Total Assets | 333 | 433 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
1 | 7 | |
-25 | -11 | |
28 | 6 | |
Net Cash Flow | 4 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Debtor Days | 198 | 64 |
Inventory Days | 96 | 35 |
Days Payable | 209 | 49 |
Cash Conversion Cycle | 85 | 50 |
Working Capital Days | 98 | 54 |
ROCE % | 20% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
17 September 2025 - Virtual investor meeting on 22 Sep 2025 01:00 PM IST by Arihant Capital.
-
Copy of Newspaper Publication
3 September 2025 - Notice of 10th AGM; annual report FY2024-25 dispatched; e-voting intimation; published Sep 03, 2025.
-
Record Date
2 September 2025 - Record date Sept 18, 2025 for final dividend Rs0.50/share; AGM Sept 25, 2025.
-
Shareholders meeting
2 September 2025 - AGM Sept 25, 2025; final dividend ₹0.50/share; MD reappointments; MD salary ₹2,29,20,000 p.a.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 September 2025 - Remus schedules virtual analyst/investor group meeting on 11 Sep 2025 at 4:00 PM IST.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing